Online inquiry

IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4082MR)

This product GTTS-WQ4082MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IGF1&IGF2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000618.5; NM_000612.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3479; 3481
UniProt ID P05019; P01344
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4082MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5128MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ15757MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA WX-G250
GTTS-WQ13114MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ14810MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ12185MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ4492MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ1792MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ5794MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA cetuximab-IR700
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW